CARDIOL THERAPEUTICS INC-A
CRDLNASDAQUS Equity
$449.02▲ $26.09 (+5.81%)
Simulated price1h—
24h▲ 5.8%
7d▲ 33284.4%
14d▲ 38776.2%
30d▲ 42663.8%
1y▲ 39991.1%
🏦Market Cap
$158.61B
Mid Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
61
Fair
Trading Snapshot
- Day Range
- $444.65 – $452.34
- 52-Week Range
- —
- Volume
- $1.90B
- Avg Volume
- $2.53B
- Shares Outstanding
- 115.2M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $23.67B
- Last Q Revenue
- $5.84B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own CRDL
- ✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$23.67B▲ +48.3% YoY
Gross Margin (TTM)
56.6%▲ +2.1% YoY
Operating Income (TTM)
$5.35B▲ +48.3% YoY
Free Cash Flow (TTM)
$7.01B▲ +48.3% YoY
About CARDIOL THERAPEUTICS INC-A
A company profile for CARDIOL THERAPEUTICS INC-A isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Price Target
ⓘAverage Target
$441.29
▼ −1.7% Downside
High Target$530.35
Low Target$337.41
Based on 22 analysts
Latest News & Updates
🚀
Reuters·2h ago
CARDIOL THERAPEUTICS INC-A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift CRDL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
CARDIOL THERAPEUTICS INC-A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.